A Randomized, Phase 2a, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
Overview
- Phase
- Phase 2
- Intervention
- VX-135
- Conditions
- Chronic Hepatitis C
- Sponsor
- Alios Biopharma Inc.
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Safety
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.
Detailed Description
Up to twenty (20) subjects with CHC GT1 infection will be randomized in a 1:1 ratio (with stratification by IL-28B genotype (CC versus non-CC)) to evaluate VX-135 low dose or high dose both given in combination with RBV for 12 weeks. Safety and tolerability will be evaluated on an ongoing basis through assessment of adverse events (AEs), lab evaluations and physical examinations. Subjects will be monitored from Day 1 through end of follow-up for virologic breakthrough or relapse.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects (male and female) must be between 18-60 years of age
- •Subjects must have Chronic Hepatitis C
- •Subjects must be treatment naive
- •Subjects must have laboratory values at screening within limits as specified by the protocol
Exclusion Criteria
- •Evidence of cirrhosis
- •Female subjects who are pregnant or nursing or male subjects with a female partner of childbearing potential who is unwilling to adhere to the contraception requirements, is pregnant or nursing, or planning to become pregnant during the study
- •any other cause of significant liver disease in addition to hepatitis C
- •Diagnosis of or suspected hepatocellular carcinoma
Arms & Interventions
VX-135 low dose in combination with ribavirin
12 weeks of VX-135 in combination with ribavirin
Intervention: VX-135
VX-135 low dose in combination with ribavirin
12 weeks of VX-135 in combination with ribavirin
Intervention: Ribavirin
VX-135 high dose in combination with ribavirin
Intervention: VX-135
VX-135 high dose in combination with ribavirin
Intervention: Ribavirin
Outcomes
Primary Outcomes
Safety
Time Frame: Week 12
The safety and tolerability as assessed by evaluating adverse events and laboratory testing.
Secondary Outcomes
- evidence of HCV RNA viral load reduction(16 weeks)